Skip to main content

Diabetes Drug News

Diabetes Drugs are responsible for helping to decrease blood sugar levels so that you can try to stay in a healthier range and help avoid serious complications.

Metformin     Insulin     SGLT-2     GLP-1     DPP-4     Combo drugs     Sulfonylureas     TZDs

On December 11, Orexigen announced the resubmission of its weight management drug Contrave (naltrexone/bupropion) to the FDA. The company has previously stated that it...
On December 27, Takeda announced that it would stop development of TAK-875 (fasiglifam) due to liver safety concerns – this was one of the most unfortunate announcements...
On November 25, the FDA announced the removal of the major restrictions on the prescription and use of GlaxoSmithKline’s Avandia (rosiglitazone) for type 2 diabetes...
On November 22, J&J/Janssen Cilags’ SGLT-2 inhibitor Invokana (canagliflozin) was approved in Europe. This makes Invokana the second SGLT-2 inhibitor approved in...
On January 8, the FDA approved Farxiga (dapaglifozin) for the treatment of type 2 diabetes. The drug is called Forxiga in Europe, where it has been approved since...
We travel to Oregon to support test strip access for people with diabetes. Find out what transpired!
The three top trends we saw in diabetes in 2013.
For World Diabetes Day on November 14, Abbott released a cool new interactive infographic about A Day in the Life of an Insulin-Using Patient . Approximately 26% of the...
Halozyme announced recently that Yale researchers have started a 20-patient artificial pancreas study (which is still recruiting) that will test the ability of...
Eli Lilly announced in October the submission of dulaglutide, its once-weekly GLP-1 receptor agonist for type 2 diabetes, in the US and Europe. This means a regulatory...
All about diabetic macular edema (DME) and three tips for avoiding it.
A major need for the 79 million Americans with prediabetes…
On Tuesday October 15, JDRF and PureTech announced the launch of T1D Innovations, an exciting new fund that aims to supply crucial funding for the development of type 1...
On September 12, Sanofi announced that it withdrew the FDA application for its once-daily GLP-1 agonist lixisenatide (named Lyxumia in Europe) for type 2 diabetes. It is...
Last month, in early September, results from the DPP-4 inhibitor cardiovascular outcomes trials SAVOR-TIMI 53 (for Bristol Myers Squibb and AstraZeneca’s Onglyza) and...
Last month, the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) released its safety review of incretin-based therapies for diabetes. It...
We ask ACA expert Dr. Jack Lord all the hard questions on healthcare coverage and reimbursement.
A whole new approach to treating type 2 diabetes at diagnosis, a new type of metformin, and the benefit of adding a GLP-1 agonist to insulin.
At ADA this year, type 2 drugs for type 1 diabetes show lots of promise. Plus, the latest exciting data on the Medtronic Veo and hypoglycemia.
At the ADA meeting. Biodel, Latitude, and Xeris had notable announcements on their glucagon programs. First, Biodel demonstrated a prototype of its new glucagon rescue...

Pages